Who are Xanomeline and Trospium Chloride's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xanomeline-and-trospium-chloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Xanomeline and Trospium Chloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xanomeline and Trospium Chloride (Xanomeline and Trospium Chloride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist. Area: Psychiatry / Neurology.

marketed Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Xanomeline and Trospium Chloride (Xanomeline and Trospium Chloride) — Collaborative Neuroscience Research, LLC. Xanomeline is a muscarinic M1/M4 receptor agonist combined with trospium chloride, an anticholinergic agent, to enhance cognitive function while mitigating peripheral cholinergic side effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xanomeline and Trospium Chloride TARGET	Xanomeline and Trospium Chloride	Collaborative Neuroscience Research, LLC	marketed	Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist	Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist class)

Collaborative Neuroscience Research, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xanomeline and Trospium Chloride — Competitive Intelligence Brief. https://druglandscape.com/ci/xanomeline-and-trospium-chloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab